Natera Sinks 14% as CEO Steve Chapman Steps Down Despite Q3 Beat: “An Excellent Time to Transition”
Natera (NTRA) fell 14% despite Q3 revenue of $794M (up 34% YoY) and raised 2026 guidance to $3.005B-$3.035B. Loss of $0.42/share exceeded estimates, and spending plans increased. CEO Steve Chapman stepped down, succeeded by Solomon Moshkevich. Clinical volume for MRD tests grew 56%.
How this was made
The 30-second read
Why it matters
The earnings surprise and leadership change drove a 14% after‑hours decline, indicating short‑term bearish pressure despite top‑line strength.
Market read
The news directly affects Natera's stock and may influence sentiment across the liquid biopsy sector.
What to watch
Potential upside from the 56% surge in MRD test volume and the new CEO's clinical diagnostics background.
Background
Natera (NTRA) posted Q3 results with revenue above expectations, raised 2026 revenue guidance, but missed earnings expectations and announced a CEO transition.
Ticker impact
Natera reported a Q3 revenue beat, raised 2026 guidance, posted a larger loss and announced a CEO transition, causing the stock to drop 14% after hours.
likely further downside as investors price in the larger loss, increased spending and leadership uncertainty
The combination of a wider-than-expected loss, higher SG&A/R&D spend, and an unexpected CEO departure typically pressures the share price despite revenue beat.
Market effects
Highlights cost pressure in the liquid biopsy sector, potentially prompting peers to reassess spending guidance.
US biotech stocks may see short-term weakness as investors digest higher expense guidance.
Limited to biotech/diagnostics investors; no broad macro impact.
Counterpoint
The revenue beat and raised long-term guidance could support a rebound if the market overreacts to the loss and leadership change.
Key entities
- CompanyNatera
Genomics diagnostics firm reporting Q3 results and CEO change.
